Imaavy: Dosage Form, Projected Sales, NCE-1 Date | Nipocalimab-Aahu

Imaavy

Imaavy is an IV antibody for adults and teens aged 12 and older with generalized myasthenia gravis who test positive for AChR or MuSK antibodies. It targets and blocks the FcRn receptor to reduce harmful autoantibodies and improve muscle strength.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

Molecule Name :

Nipocalimab-Aahu
Innovator :

JANSSEN BIOTECH, INC.
Approval Date :

29-Apr-25
Data Exclusivity Expiry :

29-Apr-29
Market Exclusivity Expiry :

29-Apr-37
Dosage Form :

Injection
Strength :

300MG/1.62ML and 1200MG/6.5ML
Therapeutic Category :

Immunomodulators
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2026 :

210
2027 :

600
2028 :

947
2029 :

1340
2030 :

1595
2031 :

1823
2032 :

2022

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Imaavy

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?